AAPL vs LLY: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Apple Inc. · Technology
$260.88
+135.9% upside to fair value
Grade B
High Quality
VS
Eli Lilly and Company · Healthcare
$939.47
+71.1% upside to fair value
High Conviction
Grade A
QuantHub Verdict
AAPL has more upside to fair value
(+135.9%).
LLY trades at a lower forward P/E
(27.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
LLY |
| Current Price |
$260.88 |
$939.47 |
| Fair Value Estimate |
$615.48 |
$1,607.00 |
| Upside to Fair Value |
+135.9%
|
+71.1%
|
| Market Cap |
$3,834.4B |
$887.6B |
| Forward P/E |
32.6x
|
27.4x
|
| EV / EBITDA |
25.4x
|
35.8x
|
| Price / Sales |
8.8x
|
14.8x
|
| Price / FCF |
31.1x
|
107.6x
|
| Revenue Growth YoY |
+40.3%
|
+44.7%
|
| Gross Margin |
47.3%
|
83.8%
|
| Operating Margin |
32.4%
|
45.6%
|
| Return on Equity |
159.9%
|
77.8%
|
| Dividend Yield |
0% |
0.56% |
| FCF Yield |
3.21%
|
0.93%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Apple Inc. is a leading technology company specializing in consumer electronics, software, and services with a strong brand and durable competitive advantages. The business quality is high, demonstrated by exceptional profitability metrics including a 159.9% return on equity, 40.3% revenue growth year-over-year, and 53.3% earnings growth year-over-year. Despite these fundamentals, the stock is cu…
Eli Lilly remains the dominant GLP-1 franchise holder with Mounjaro and Zepbound generating $36.5B combined in 2025 on 45% total revenue growth to $65.2B. The company guided $80-83B for 2026, well above prior Street consensus, and launched Foundayo (oral GLP-1, FDA approved April 2026) with $1.5B pre-built inventory. At $939 the stock trades at 14.8x P/S, right at its 5-year median, and 27.4x for…
Accumulation Zones
| Metric |
AAPL |
LLY |
| Zone Low |
$461.61 |
$1,205.00 |
| Zone High |
$523.16 |
$1,366.00 |
| In Buy Zone? |
Yes
|
Yes
|